By: P. Vlummens MD
Now that the anti-CD38 monoclonal antibodies have shown their potency and usefulness, it seems that EHA 2017 gave us the opportunity to direct our gaze towards the other novel players emerging in the therapeutic field of multiple myeloma (MM). As such, the aim of this article is to focus on some of the earlier phase trials, revealing interesting results concerning potentially potent therapeutic and supportive strategies.
(BELG J HEMATOL 2017;8(4):133–6)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
